0001127602-22-026832.txt : 20221202 0001127602-22-026832.hdr.sgml : 20221202 20221202183359 ACCESSION NUMBER: 0001127602-22-026832 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stonehouse Jon P CENTRAL INDEX KEY: 0001385496 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 221443295 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-12-01 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001385496 Stonehouse Jon P 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 1 President & CEO Common Stock 2022-12-01 4 M 0 214917 1.42 A 1116747 D Common Stock 2022-12-01 4 S 0 214917 13.00 D 901830 D Common Stock 2022-12-02 4 M 0 82656 1.42 A 984486 D Common Stock 2022-12-02 4 S 0 82656 12.80 D 901830 D Common Stock 5000 I By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust Common Stock 5000 I By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust Emp. Stock Option (Right to Buy) 1.42 2022-12-01 4 M 0 214917 0 D 2014-01-01 2023-01-01 Common Stock 214917 82656 D Emp. Stock Option (Right to Buy) 1.42 2022-12-02 4 M 0 82656 0 D 2014-01-01 2023-01-01 Common Stock 82656 0 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. /s/ Alane P. Barnes, by power of attorney 2022-12-02